["{\n\"step_by_step_thinking\": \"The question is about natalizumab's effect on secondary progressive multiple sclerosis. The relevant documents provide information on the clinical course of multiple sclerosis, but there is no specific mention of natalizumab or its impact on disease progression. However, an article on experimental therapies for multiple sclerosis might be relevant, as it discusses various treatments, including those that are not currently FDA-approved. Unfortunately, natalizumab is not mentioned in this document either. The articles do provide information on the clinical course of multiple sclerosis, including the frequency and spectrum of morbidity, which could be used to inform treatment decisions, but they do not specifically address the effect of natalizumab.\",\n\"answer_choice\": B"]